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Abstract
Nanoparticles can be engineered with distinctive compositions, sizes, shapes, and surface 
chemistries to enable novel techniques in a wide range of biological applications. The unique 
properties of nanoparticles and their behavior in biological milieu also enable exciting and 
integrative approaches to studying fundamental biological questions. This review will provide an 
overview of various types of nanoparticles and concepts of targeting nanoparticles. We will also 
discuss the advantages and recent applications of using nanoparticles as tools for drug delivery, 
imaging, sensing, and for the understanding of basic biological processes.
1. INTRODUCTION
Nanotechnology is a relatively new branch of science that has found a wide range of 
applications that range from energy production to industrial production processes to 
biomedical applications.1 One of the key applications is in biology and biomedical research. 
Nanoparticles (NPs) can be engineered to possess unique composition and functionalities, 
which can provide novel tools and techniques that have not previously existed in biomedical 
research. For example, NPs can be used to image biological processes on the cellular level. 
They can also be utilized to detect analytes at the attomolar range. In this review, we aim to 
discuss the types of NPs and their potential application in biology and biomedical research.
2. TYPES OF NANOPARTICLES
There are many types of NP platforms with differing size, shape, compositions, and 
functionalities. Furthermore, each type of NPs can potentially be fabricated using different 
techniques, such as both nanoprecipitation and lithography for polymeric NPs. While it is 
not within this manuscript’s scope to discuss the differences in NP platforms and their 
fabrication in detail, we will discuss the major characteristics and functionalities of each NP 
that are relevant for biomedical research.
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The first NP platform was the liposomes. Liposomes were first described in 1965 as a model 
of cellular membranes.2 Since then, liposomes have moved from a model in biophysical 
research to one of the first NP platforms to be applied for gene and drug delivery. 
Liposomes are spherical vesicles that contain a single or multiple bilayered structure of 
lipids that self-assemble in aqueous systems.3 Unique advantages imparted by liposomes are 
their diverse range of compositions, abilities to carry and protect many types of 
biomolecules, as well as their biocompatibility and biodegradability.3–4 These advantages 
have led to the well-characterized and wide use of liposomes as transfection agents of 
genetic material into cells (lipofection) in biology research.5 Lipofection generally uses a 
cationic lipid to form an aggregate with the anionic genetic material. Another major 
application of liposomes is their use as therapeutic carriers since their design can allow for 
entrapment of hydrophilic compounds within the core and hydrophobic drugs in the lipid 
bilayer itself.6 To enhance their circulation half-life and stability in vivo, liposomes have 
been conjugated with biocompatible polymers such as polyethylene glycol (PEG).3 
Liposomes can also be functionalized with targeting ligands to increase the accumulation of 
diagnostic and therapeutic agents within desired cells. Today, there are twelve clinically 
approved liposome-based therapeutic drugs.
Albumin-bound
Albumin-bound NPs (nab) uses the endogenous albumin pathways to carry hydrophobic 
molecules in the bloodstream.7 Albumin naturally binds to the hydrophobic molecules with 
non-covalent reversible binding, avoiding solvent-based toxicities for therapeutics.8 As a 
result, this platform has been successfully adapted as drug delivery vehicle. Abraxane, a 
130-nm nab paclitaxel was approved by the FDA in 2005 for the treatment of metastatic 
breast cancer.9 Abraxane concentrates in cells through albumin receptor (gp60)-mediated 
transport in endothelial cells. It may also target the albumin-binding protein SPARC 
(secreted protein acidic and rich in cysteine), which is overexpressed in certain tumors.10 
Further understanding of the mechanism of action may lead to better targeting and 
development of novel therapeutics using the nab platform.
Polymeric
Polymeric NPs formed from biocompatible and biodegradable polymers have been 
extensively investigated as therapeutic carriers.11 Polymeric NPs are formulated through 
block-copolymers of different hydrophobicity.12 These copolymers spontaneously assemble 
into a core-shell micelle formation in an aqueous environment.13 Polymeric NPs have been 
formulated to encapsulate hydrophilic and/or hydrophobic small drug molecules, as well 
proteins and nucleic acid macromolecules.14 The NP design can allow for slow and 
controlled release of drug at target sites. Polymeric NPs are usually able to improve the 
safety and efficacy of the drugs they carry. Functionalizing polymeric NPs with targeting 
ligands for improved drug delivery has been an important area of investigation since 
polymeric NPs are unique in their ability to be tailored prior to particle assembly. The 
incorporation of targeting ligands on the NPs can lead to their increased uptake along with 
their cargo, leading to enhanced therapeutic outcomes.
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Another type of polymeric NP is dendrimers. Dendrimers are regularly branched 
macromolecules made from synthetic or natural elements including amino acids, sugars, and 
nucleotides.15 They have a central core, interior layers of branches, and an exterior 
surface.16 The varied combination of these components can yield dendrimers of well-
defined size, shape, and branching length/density.17 As a result of their unique design, 
dendrimers can be developed as sensors as well as drug and gene delivery carriers. 
Dendrimers can be loaded with small molecules in the cavities of the cores through chemical 
linkage, hydrogen bond, and or hydrophobic interaction.18 The exterior surface can also be 
readily modified to produce chemical functional groups for molecular targeting groups, 
detecting and imaging agents, and therapeutic attachment sites.19
Iron oxide
Iron oxide NPs are widely studied as a passive and active targeting imaging agent as they 
are mainly superparamagnetic. The superparamagnetic iron oxide NP (SPION) generally 
have an iron oxide core with a hydrophilic coat of dextran or other biocompatible compound 
to increase their stability.2021 The most widely used SPIONs consist of a magnetite (Fe3O4) 
and/or maghemite (γFe2O3) core. These NPs exhibit size-dependent superparamagnetism, 
which allows them to become magnetized with the application of an external magnetic field 
and exhibit zero net magnetization upon removal of the magnetic field. SPIONs have been 
successfully used as T2-weighted magnetic resonance (MR) contrast agents to track and 
monitor cells.22 SPIONs have several advantages over conventional gadolinium-chelate 
contrast agents including decreased toxicity and increased imaging sensitivity and 
specificity.23 SPIONS can also be degraded to iron and iron oxide molecules that are 
metabolized, stored in cells as ferritin, and incorporated into hemoglobin.23 Currently, two 
SPIO agents, ferumoxides (120–180 nm) and ferucarbotran (60 nm) are clinically approved 
for MRI. SPIONs have also been used in molecular imaging applications such as the 
detection of apoptosis24 and gene expression.25 SPIONs can be functionalized with 
magnetic, optical, radionuclide and specific targeting ligands for multimodal imaging. They 
can also potentially be used as non-invasive diagnostic tools and as drug delivery vehicles.26
Quantum dot
First discovered in 1980, quantum dots (QDs) are semiconductor particles that are less than 
10 nm in diameter. QDs display unique size-dependent electronic and optical properties.27 
Most QDs studied consist of a cadmium selenide (CdSe) core and a zinc selenide (ZnS) 
cap.28 The absorption spectra of these particles are very broad and emission is confined to a 
narrow band. QDs can also emit bright colors, have long lifetimes, high efficiencies and are 
stable against photobleaching. They can be generated to have different biochemical 
specificities and can be simultaneously excited and detected. As a result, QDs have several 
significant advantages over many organic fluorophore dyes for optical applications. They 
are widely used in biological research as fluorescence imaging tools for applications such as 
cell labeling and biomolecule tracking.293028 The small size of quantum dots also enables 
them to be suitable for biomedical applications such as medical imaging and diagnostics.31
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Gold NPs offer many size-and-shape dependent optical and chemical properties, 
biocompatibility, and facile surface modification.21 Gold NPs can strongly enhance optical 
processes such as light absorption, scattering, fluorescence, and surface-enhanced Raman 
scattering (SERS) due to the unique interaction of the free electrons in the NP with light.32 
These properties have enabled the realization of gold NPs in many applications such as 
biochemical sensing and detection, biological imaging, diagnostics, and therapeutic 
applications. Sensing techniques include the use of gold NPs in colorimetric arrays and the 
use of gold NPs as substrates in SERS to significantly enhance Raman scattering, allowing 
for spectroscopic detection and identification of proteins and single molecules at the NP 
surface.33 Gold NP probes have also been used to detect heart disease and cancer 
biomarkers.3435 They can also transform absorbed light into heat and therefore, have high 
potential for infrared phototherapy.36
3. TARGETED NANOPARTICLES
The concept of targeting has become a significant focus in biological research in recent 
years. In proteomics, targeted proteomics has gained traction as an approach to address 
specific biological questions by focusing on a subset of proteins of interest.37 In genetics, 
gene targeting in mice has become a gold standard for determining gene function in 
mammals.38 In the areas of drug discovery and molecular therapeutics, the development of 
small molecules and monoclonal antibodies such as imatinib39, trastuzumab40, 
bevacizumab41, and rituximab42 have considerably changed the treatment of cancer.
NPs show much promise in biological applications. In particular, NPs offer many unique 
properties that enhance or confer advantages over current techniques in biological and 
biomedical research. As a result, there has been significant interest in applying targeting 
concepts to NP design. NPs can be targeted by active targeting and passive targeting under 
in vivo conditions.
3.1 Passive Targeting
In the case of passive targeting, NP systems have been successfully developed for cancer 
therapy by taking advantage of tumor tissue biology. Normal tissue vascular biology has an 
organized structure while tumor vasculature is irregularly branched and disorganized.43 
Tumors also have high vascular density, increased vascular permeability, and impaired 
lymphatic drainage, an attribute of solid tumors and inflamed tissue.43–44 Together, these 
features are known as the enhanced permeability and retention (EPR) effect, which allows 
NPs to accumulate preferentially in tumor tissue.44 NPs have extended retention times in 
tumor tissue, which results in higher concentrations than in other tissues. Properties that 
mediate this passive targeting process include particle composition, size, shape, and surface 
characteristics.45 Thus, NPs can be engineered to better target a particular tissue or cell by 
optimizing their physicochemical characteristics.
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Active targeting involves the use of targeting ligands for enhanced delivery of NP systems 
to a specific site. Typical targeting ligands include small molecules, peptides, antibodies and 
their fragments, and nucleic acids such as aptamers.14 These ligands have all been 
conjugated to NPs.14
Conjugating targeting ligands to NP surfaces can be performed via covalent and non-
covalent methods. With covalent conjugation, the same chemical methods for 
functionalization can be applied to various types of NPs since conjugation of functional 
groups to the NP surface is dependent on the functional groups on the NP surface and the 
functional groups of the ligand being conjugated. Certain conjugation techniques are also 
suitable for specific targeting ligand classes. The maleimide-thiol coupling is commonly 
used for conjugation of peptides, antibodies and their fragments to NPs. In this reaction, 
maleimides (maleic acid imides) spontaneously reacts with sulfhydryl groups at pH 6.5 to 
7.5. Thus, nanoparticle surfaces incorporated with maleimide modified polymers or lipids 
can be readily conjugated with targeting ligands engineered with thiol groups or cysteine, 
which has a thiol side chain. Another commonly used conjugation method is the 
carbodiimide-mediated amide coupling between carboxyls and amines to form amide bonds. 
In this reaction, carboxylate groups on a molecule can be converted to active esters by using 
a variety of carbodiimides such as the water-soluble 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC) and N-hydroxy-succinimide (NHS) or sulfo-NHS. The activated ester 
intermediate can react with a primary amine to form an amide bond. This method is 
generally preferred for aptamers, which can be modified with amines, and small molecules, 
which can contain carboxylates or primary amines. Click chemistry reactions are another 
method used to conjugate functional groups with high yield and selectivity under moderate 
reaction conditions. One of the most popular reactions with this class is the [3+2] 
cycloaddition between alkynes and azides.46
Conjugating targeting ligands to the NP surface can facilitate active targeting of NPs to 
receptors that are present on target cells, leading to enhanced cell internalization and/or 
specific uptake through receptor-mediated endocytosis.47 For NP delivery of therapeutics, 
these advantages result in higher drug concentrations and reduced systemic toxicities 
compared to non-targeted NPs and their small molecule counterparts. Thus, there has been 
intense interest in identifying new disease biomarkers and their ligands for use in targeted 
drug delivery. Targeted NPs can also identify molecular targets with good affinity and 
selectivity. These NPs can bind to analytes, pathogens, and biomarkers, amplifying their 
signal for detection and molecular imaging.
4. NANOPARTICLE APPLICATIONS IN BIOLOGY
4.1 Nanoparticles as sensors
NPs have been employed in sensors for a variety of applications including detecting analytes 
at very low concentrations, detecting and separating pathogens, detecting and capturing 
cells, and detecting molecular and cellular functions.
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4.1.1 Nanoparticles for analyte detection—The development of new sensing 
techniques for biological analytes such as DNA, RNA, and proteins are leading to more 
sensitive and efficient detection of these analytes at low concentrations. Many of these new 
techniques have taken advantage of the unique properties of NPs. NPs have large surface 
area to mass ratio, small size, and composition dependent properties that can enable the use 
of surface ligands as a way to amplify the detection threshold or provide more rapid 
detection.48 The ability to easily functionalize NPs with targeting ligands can also enable 
specificity in binding and signaling of the analytes, allowing for more efficient detection. 
Development of NP biosensors has primarily focused on the use of inorganic NPs, 
particularly metallic or magnetic NPs.
NP platforms such as gold NPs have been extensively used as sensors due to their surface 
chemistry. One method of using the unique surface chemistry of gold NPs for signal 
transduction amplification is the bio-barcode method developed by the Mirkin group. This 
method has been applied for protein49 and DNA50 target detection. For target DNA 
detection, PCR-like sensitivity can be achieved. This technique has been reported for the 
detection of cytokines at a 30 aM (attomolar) concentration range51 and for a soluble 
pathogenic biomarker for Alzheimer's disease at a concentration around 100 aM.52 More 
recently, the group used this method to detect prostate-specific antigen (PSA), a commonly 
investigated cancer biomarker that can indicate the presence of prostate cancer when 
expressed at elevated levels.53 In the bio-barcode assay approach, DNA-functionalized gold 
NPs (30 nm) are conjugated to PSA-specific antibodies to generate PSA gold NP probes 
(Figure 2).5455 The DNA strands are the bio barcodes. A magnetic microparticle (MMP) 
functionalized with monoclonal antibodies to PSA are mixed with the PSA target protein. 
After a washing step, the PSA gold NP probes are added to the MMP-bound PSA. After 
further separation by a magnetic field application and wash steps, the PSA-specific DNA 
barcodes are released into solution and analyzed using the scanometric assay, which takes 
advantage of gold NP catalyzed silver enhancement. This assay achieved a sensitivity of 330 
fg/mL of PSA.
The DNA bio-barcode method combines the ability to conjugate a large number of DNA 
strands onto gold NP surfaces and the detection of these DNAs using techniques such as 
PCR amplification or scanometric assays. Another approach for sensing that uses optical 
properties of the NP surface has been developed by the Rotello group.56 They found that 
anionic fluorescent polymers may reversibly bind and dissociate from functionalized 
cationic gold NPs through non-covalent chemical interactions. When the fluorescent 
polymer is bound to the NP, its fluorescence is quenched. When it is dissociated from the 
NP, the fluorescence is restored. This phenomenon is the basis of a “chemical nose” 
system.57 In this system, the target protein is detected according to their different 
fluorescence responses upon binding to different types of surface-modified gold NPs. A 
fluorescence response pattern is generated and then analyzed through statistical methods. 
This process can detect, quantify, and distinguish different molecular targets from each 
other. This process was initially developed for the detection and sensing of proteins,57 but 
has also been adapted for the detection and sensing of bacteria,58 for the detection of 
physicochemical differences between healthy, cancerous and metastatic human breast cells, 
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and for the differentiation of isogenic healthy and transformed cells (Figure 3).5960 
“Chemical nose” sensing also provides the advantage of not using antibodies for detection 
since the identity of the target analyte does not need to be known in order to detect the 
analyte.
Gold NPs can also enhance surface-enhanced Raman scattering (SERS) for detection of and 
identification of biomolecules at the NP surface. The technique SERS has been frequently 
used to detect specific analytes through their unique vibrational spectra. The narrow width 
of SERS spectra allows for multiple analyte detection within complex mixtures, including 
detection down to the single-molecule level.33 Thus, SERS have been used for ultrasensitive 
detection of biomolecules such as glucose,61 hemoglobin,62 bacteria,63 and viruses.64 Using 
this approach, a group demonstrated that gold NPs encoded with Raman reporters and 
conjugated with single-chain variant fragment (ScFv) antibody can target cancer biomarkers 
such as epidermal growth factor receptors (EGFR) in vitro and in vivo (Figure 4).6566 
Recently, investigators also demonstrated a SERS system based on a thin-film NP array self-
assembled at the liquid/liquid interphase for multi-phase trace analyte detection.67 The 
group was able to detect single phase analytes as well multiple analytes dissolved in water 
and organic phases.
Nanosensors have also been developed that exploit the magnetic properties of magnetic NPs 
such as SPIONs. There is considerable interest in magnetic NPs since they have strong 
magnetic properties and most biological samples exhibit negligible magnetic 
susceptibility.68 SPIONs have been used as magnetic tags for many different types of 
sensors including giant magnetoresistive (GMR) biosensors, which are based on the binding 
of magnetic particles to a sensor surface.69 The magnetic fields of the particles can alter the 
magnetic fields of the sensor, resulting in changes in the electrical resistance of the sensor. 
Recently, Wang and colleagues at Stanford University have demonstrated the use of this 
technique for a protein detection assay in which an array of GMR sensors is used to detect 
binding events of proteins to arrays of surface-bound antibodies with the use of SPIONS as 
magnetic tags.70 In this assay, the target antigen is between two antibodies, one bound to the 
sensor and the other tagged with a SPION. The presence or absence of the magnetized NP is 
detected by the underlying sensor. The group demonstrated the assay to be matrix 
insensitive to various biological fluids, but still capable of detecting proteins down to 
attomolar concentrations and over an extensive range of concentrations. Using a similar 
strategy, they have also demonstrated the detection of cancer-associated proteins in 50% 
serum at sub picomolar concentrations using MACS particles (commercialized SPIONs for 
cell separation).71 Recently, they have used streptavidin functionalized antiferromagnetic 
NPs to detect DNA with high sensitivity (10 pM).72
The superparamagnetic property of IONPs is also the basis of magnetic relaxation switching. 
The Weissleder group has studied magnetic relaxation switches consisting of 3–5 nm 
SPIONs coated with 10 nm thick dextran and stabilized by crosslinking.73 Targeted SPIONs 
are developed by functionalizing them with amino groups for the attachment of a range of 
sulfhydryl-bearing molecules.74 The nanoswitches can undergo reversible assembly 
(clustering and declustering) in the presence of a molecule that is recognized by the ligands 
immobilized on the NP, resulting in a change in the transverse magnetic relativity (1/T2) of 
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surrounding water protons. The changes in relaxation rates as a result of NP assembly can be 
used to detect a variety of biological targets including DNA and proteins at the low 
femtomole level (0.5–10 fmol).75 Recently, the Weissleder group developed a portable chip-
based diagnostic magnetic resonance (DMR) system for rapid and quantitative detection of 
biological targets.76 The DMR also uses IONPs as sensors to amplify molecular interactions 
caused by assemblies of SPIONs. They demonstrated proof of concept by detecting with 
high sensitivity the presence of proteins in parallel and by detecting bacteria. Compared to 
the benchtop NMR relaxometer, the DMR system showed a mass detection limit improved 
by two orders of magnitude (detection limit of 15 fmol).
Magnetic NP relaxation sensors have also been used in which the basis of the assay is the 
relaxation of the magnetic moments within magnetic NPs.77 Brownian relaxation is the 
dominant mechanism for these NP biosensors. In this method, NPs form aggregates in 
recognition of target analytes, leading to a larger hydrodynamic size and thus slower 
Brownian relaxation responses than individual NPs. Using this principle, a group recently 
detected a bacterial antibody at the sensitivity of 0.3 nM with an AC susceptometer78.
4.1.2 Nanoparticles for pathogen detection and separation—Various NP 
platforms have been explored as sensors for detection and separation of pathogens. Most 
strategies for pathogen detection have utilized optical and magnetic properties of NP 
platforms. One of the most common methods used for the detection of bacteria has been 
through the use of magnetic biosensors that involves direct immunological reactions using 
magnetic NPs coated with antibodies against surface antigens.7980 One group applied this 
immunomagnetic approach in a novel microfluidic device to attract molecules bound to 
magnetic NPs from one laminar flow path to another via a local magnetic field gradient.80 
Using this device, E. coli labeled with biotinylated anti-E.coli antibody and bound to 
streptavidin-coated SPIONs were efficiently separated from solutions containing densities of 
red blood cells similar to blood.
The Weissleder group has also used antibody-coated NPs in a microfluidic device to detect 
bacteria.81 They also reported that core/shell NPs with Fe metal cores have enhanced 
sensitivity compared to IONPs for the detection of bacterial cells. Recently, the group also 
developed an assay based on a magnetic barcoding strategy that did not require antibodies 
and could detect single-gene mutations.82 In this approach, PCR-amplified mycobacterial 
genes are sequence-specifically captured on polymeric beads that are modified with 
complementary DNA, labeled by SPIONs, and detected by NMR. The platform could detect 
M. tuberculosis and identify drug-resistance strains from sputum samples within 2.5 h. The 
investigators also developed a similar system that uses rRNA as a target marker for NP 
labeling.83 The approach used a universal and specific nucleic acid probes that detects 16S 
rRNA, which is abundant in and common to many bacterial species. The device was 
sensitive enough to detect as few as 1–2 E. coli bacteria in 10 ml of blood and accurately 
estimate bacterial load.
Many groups have also utilized small molecule functionalized NPs to effectively label 
bacteria. One group developed a magnetic glyco-NP based system that could detect E. Coli 
strains in 5 minutes as well as enabling up to 88% removal from the sample by exploiting 
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the bacterial interaction with carbohydrates on mammalian cell surfaces (Figure 5).8485 
Another group reported the use of vancomycin-modified SPIONs in a magnetic capture 
assay for various Gram-positive and Gram-negative bacteria.86 They also demonstrated that 
as size and ligand coverage on the NP increases, the time required for efficient labeling to 
the bacteria with the NPs decreases.
Optical biosensing of bacteria has also been employed using both metallic NPs and QDs. 
The bio-barcode assay approach49 provides amplification and the possibility of 
simultaneously detecting many different targets in one sample. Using this method, Bacillus 
subtilis double-stranded genomic DNA was detected at a 2.5-fM concentration.87 Similarly, 
Salmonella enteritidis was detected a0.2 fM.88 QDs have also been used as pathogen 
sensors. Edgar et al. reported a technique that combined in vivo biotinylation of engineered 
host-specific bacteriophage and attachment of the phage to streptavidin-coated QDs.89 The 
method provides specific detection of E. coli among several different bacterial strains and 
can detect as few as 10 bacteria/mL of the experimental samples.
4.1.3 Nanoparticles for cell detection and separation—Efficient isolation of 
specific cells from complex mixtures is necessary for biological research and for many 
biological applications. NPs have been explored as sensitive tools for the detection of 
specific cell types and cells found in low frequency. One application of interest has been the 
detection and capture of circulating tumor cells (CTCs). CTCs can aid in the understanding 
of the biology of cancer metastasis and have been described as a strong prognostic 
biomarker for overall survival in patients with metastatic breast, colorectal, and prostate 
cancer.9091
NP immunomagnetic techniques are some of the more commonly used methods for the 
identification and capture of CTCs. These techniques involve the use of magnetic NPs to 
target and isolate CTCs using a ligand-receptor based mechanism. Currently, the CellSearch 
device, which uses an immunomagnetic technique, is the only FDA-approved test for CTC 
assessment.9291 CellSearch is based on a positive epithelial cell adhesion molecule 
(EpCAM) selection of the CTCs and utilizes iron NPs coated with a polymer layer carrying 
biotin analogues and conjugated with anti-EpCAM, for the capture of CTCs in vitro. This 
system can also be used for the labeling and identification of leukocytes using an anti-
CD45-APC as the NP targeting ligand. Recently, a group also demonstrated that IONPs 
functionalized with anti-HER2 or anti-HER2/neu could be used to separate 73.6% of 
HER2/neu over-expressing cancer cells that were spiked in 1 mL of blood.93 The receptor-
ligand interactions resulted in the preferential capture of the cancer cells. In another 
preclinical study, in vivo CTC detection approach was achieved using PEGylated magnetic 
NPs.94 Investigators dually targeted CTCs in vivo with magnetic NPs conjugated with 
plasminogen activator (uPA) and folate-targeted nanotubes for subsequent detection with 
photoacoustic flow cytometry.
The incorporation of polymers, which can enable targeted detection and surface capturing, 
to other organic and inorganic NP platforms can potentially lead to novel NP sensors for 
CTC detection.95 Recently, a group used targeted polymer coated gold NPs and the SERS 
technique to directly measure CTCs in the presence of white blood cells (Figure 6).9697 EGF 
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peptides were conjugated to the polymer coated gold NPs that were encoded with QSY 
reporters. The NPs successfully identified CTCs in the peripheral blood of 19 patients with 
squamous cell carcinoma of the head and neck, with a sensitivity range of 1 to 720 
CTCs/mL of whole blood.
Other techniques for identification and separation of cells include the use of biomimetic 
nanotechnology, which takes advantage of naturally occurring processes. The Hong group 
has investigated biomimetic approaches to develop microfluidic devices for the 
identification and separation of cells. These devices exploit the natural process of cell 
rolling, which results from adhesive interactions between selectin molecules expressed on 
the endothelial venules and glycoprotein receptors on the cancer cells-98 -Recently, the cell 
rolling process using E-selectin was applied to CTC detection for enhanced surface 
sensitivity and specificity.100 Seventh-generation (G7) poly(amidoamine) (PAMAM) 
dendrimers were also used to engineer cell capture surfaces for simultaneous binding of 
multiple ligands to multiple receptors (multivalent binding). The biomimetic combinations 
of dendrimer-mediated multivalent effect and cell rolling significantly enhanced the surface 
capture of CTCs.
4.2 Nanoparticles as imaging agents
NPs have been explored as novel labels and contrast agents in molecular imaging. The 
unique properties of NPs can enable sensitive and specific monitoring of molecular targets 
as well as of cell responses associated with diseases such as cancer and cardiovascular 
diseases.101
4.2.1 Nanoparticles for targeted imaging—NPs have many promising attributes for 
targeted imaging. First, NPs can deliver a large number of imaging agents at a time due to 
their surface area, allowing for improvement in sensitivity.109 Second, NPs may passively 
target tissues in vivo via the EPR effect or be targeted to accumulate at sites where the 
molecular target is expressed, increasing the local concentration of contrast agents. The high 
capacity for NP modification enables their use as amplifiers for in vivo imaging. Finally, 
they can deliver several different types of imaging agents to perform multimodality imaging.
Inorganic NPs such as QDs are among the most promising fluorescent labels for cellular 
imaging. QDs can emit light of specific wavelengths and also be tuned to emit in the NIR 
region of the spectrum, in which tissue autofluorescence is reduced and excitation light 
penetration increased.110 Monofunctionalized QDs have been used to track individual 
proteins in cells111 and for receptors involved in cell movement during development and 
metastasis.112 QDs have been used for imaging of specific tumor biomarkers, such as the 
use of aginine-glycine-aspartic acid (RGD) peptide-conjugated NIR QDS for the targeting of 
integrin αvβ3.113 Targeted QDs have also been studied for their capability for multiplex 
imaging, which involves simultaneous imaging of many molecular targets using different 
QDs that use different emission wavelengths. Recently, QDs have been applied for 
multiplex molecular imaging of lymph nodes114, embryonic stem cells115, as well as tumor 
cells and vasculature.116117
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Gold NPs have been studied as a non-invasive modality for in vivo cancer imaging using 
small organic molecules as near-infrared (NIR) SERS reporters. Recently, antibody 
conjugated gold NPs have been used in conjunction with a sensitive and stable cyanine 
reporter that developed and screened from a combinatorial library of SERS reporters for the 
detection of HER2-positive tumors in xenograft models.118 Other recent in vivo imaging 
efforts have been directed towards the use of several targeted SERS gold NPs for 
multiplexed imaging in mouse models.119120
One of the more well studied NP platforms for molecularly targeted imaging are magnetic 
NPs. Magnetic NP imaging systems have shown potential for real-time visualization of 
biological events, such as cell migration/trafficking,121122123enzyme activities124, and other 
biological interactions at the molecular and cellular level.25 Magnetic NPs have also shown 
promising use as contrast agents in magnetic resonance imaging (MRI), a biomedical 
technique based on nuclear magnetic resonance of various interacting nuclei. SPIONs, 
formed from iron oxide crystals coated with dextran or carboxydextran, is a widely used 
MRI contrast agent for cancer imaging.20 When injected into patients, SPIONs have been 
shown to remain the tumors 24 hours after injection compared with 1 hour for gadolinium-
based MR agents.125 This difference is due to easier uptake of the NP by tumor tumors and 
lower diffusivity of the NP out of the tumor.
Many studies have investigated the use of SPIONs for the targeted detection of tumors and 
their metastases,126127128129 and apoptotic tumor tissues.24 SPIONs have also been targeted 
to cancer cells without using targeting ligands. In one study, it was demonstrated that a 
recombinant human heavy-chain ferritin protein shell containing IONPs targeted tumor cells 
overexpressing transferrin receptor 1.130 The iron oxide core also catalyzed the oxidation of 
peroxidase substrates in the presence of hydrogen peroxide to produce a color reaction that 
is used to visualize tumor tissues. In another study, investigators assembled SPIONs and 
targeting peptides on a modified viral scaffold to increase the number of SPIONs reaching 
tumor cells.129 Glutamic acid residues were introduced into the protein coat of M13, a virus 
that infects bacteria. The negative charged residues promoted the electrostatic assembly of 
NPs along the M13 coat’s filamentous structure. The viral coat was also rendered to display 
a peptide that targets SPARC glycoprotein, which is overexpressed in various cancers. 
Compared to traditional approaches where NPs are directly functionalized with targeting 
ligands, this approach may amplify the contrast when performing MR imaging.
Novel NPs with advanced magnetic properties have also been pursued for visualizing 
biological events. One such class is metal-doped ferrite NPs with a composition of MFe2O4, 
where M is +2 cation of Mn, Fe, Co or Ni, to tune specific magnetic properties.127 MnFe2O4 
NPs were found to be non-toxic in vitro and possess the highest magnetic susceptibility, 
suggesting that they may make better MRI probes. When these NPs were conjugated with 
antibodies, they showed enhanced MRI sensitivity for the detection of cancer markers. Other 
NP platforms have been combined with SPIONS including dendrimers 
(magnetodendrimers)123 and liposomes (magnetoliposomes)131. These SPIONs have been 
used for applications such as monitoring the migration of cells or visualizing bone marrow 
in vivo.132
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4.3 Nanoparticles as Delivery Vehicles
4.3.1 Delivering siRNA for biological studies—RNA interference (RNAi) is an 
important biological tool for use in cell culture and in living organisms. It is traditionally 
used to study gene functions because it allows targeted degradation of mRNA after the 
introduction of sequence-specific double stranded RNAs into cells. However, effective 
siRNA delivery can require overcoming many biological obstacles: 1) difficulty entering the 
cell because of high molecular weight and negative charges, 2) degradation by nucleases 
within the cell, 3) targeting to the appropriate cell compartment and 4) rapid clearance and 
instability in vivo.133134135 Therefore, to realize the potential of RNAi, efficient and 
biocompatible delivery systems are needed.
NPs offer a potential solution to the challenges in siRNA delivery. Cationic lipid or polymer 
NPs have been used to transport anionic nucleic acids into cells due to their ability to form a 
condensed complex with nucleic acids.136 This stabilizes and protects them from enzymatic 
degradation. Cationic materials can also help NPs escape sequestration in endosomes/
lysosomes. Groups such as the nitrogens in the cationic polymer polyethyleneimine (PEI), 
which become protonated in the pH environment of the endosome/lysosomes, can facilitate 
endosomal escape by increasing Cl− influx in response to protonation at acidic pH. The 
result is an increase in osmotic pressure and swelling, which leads to organelle burst and 
delivery of the siRNA NPs. This phenomenon is referred to as the “proton sponge effect”. 
However, a recent study showed that siRNA delivery in a cationic lipid NP system was 
substantially reduced as approximately 70% of the internalized siRNA were recycled to the 
extracellular media due to the exiting of the lipid NPs from late endosomes/lysosomes.137 
Thus, siRNA delivery might be improved by designing novel NP vehicles that can escape 
the recycling pathways. Active targeting methods of non-endocytic uptakes of NP delivery 
of nucleic acids have been also been explored using fusogenic peptides and cell penetrating 
peptides.138 To better understand siRNA NPs interactions with biological systems, siRNA 
probes have been used to study intracellular trafficking139 as well as assembly and 
disassembly of siRNA NPs.140
Recently, NPs have been used to deliver siRNA to silence genes in immune cells since these 
cells can have pivotal roles in homeostasis and disease.141 In one study, NPs were used to 
selectively silence Cyclin D1 (CyD1), a cell cycle–regulatory molecule, in leukocytes in 
vivo to determine the exact roles of the molecule in gut inflammation.141 NPs were loaded 
with CyD1 siRNA and functionalized with antibodies to β7 integrin. The study revealed that 
these targeted NPs silenced CyD1 in leukocytes and reversed experimentally induced colitis 
in mice by suppressing leukocyte proliferation and T helper cell 1 cytokine expression. 
Another recent report also described the use of lipid NPs for the in vivo delivery of siRNA to 
silence disease genes in immune cells.142 The study demonstrated siRNA-mediated 
silencing in myeloid cell types of nonhuman primates and established the feasibility of 
targeting multiple gene targets in rodent myeloid cells. The therapeutic potential was 
validated using siRNA targeting tumor necrosis factor-α (TNFα). Another study used NPs 
to explore the immunological mechanisms triggering nonalcoholic steatohepatitis 
(NASH).142 The investigators found that TNFα produced by Kupffer cells can trigger the 
development of NASH through the enhanced production of chemokines IP-10 and MCP-1. 
Wang and Wang Page 12






















Moreover, TNFα silencing in myeloid cells reduced the chemokine production and 
prevented the development of NASH, suggesting potential of TNFα as a novel therapeutic 
target in NASH.
NPs have also been used as a vehicle to deliver siRNA in plant cells to study cellular 
pathways at the single cell level.143 One group used amine-conjugated polymeric NPs as 
vehicles to siRNAs targeting specific genes in the cellulose biosynthesis pathway. They 
found that NtCesA-1, a factor involved in cell wall synthesis in whole plants, also plays an 
essential role in cell wall regeneration in isolated protoplasts.
4.3.2 Delivering hydrophobic compounds without solvent or excipients—Many 
biologically active compounds are hydrophobic molecules and are poorly soluble in water. 
Utilizing such compounds in biological research can be challenging because of their poor 
solubility in aqueous environments. Current approaches involving using a solvent such as 
dimethyl sulfoxide (DMSO) or an excipient such as cremophor. However, not all 
compounds can be solubilized using these solvents and the solvents themselves frequently 
incur toxicities from living organisms that can complicate the biological experiment. For 
example, wortmannin, a PI3 kinase inhibitor and a commonly utilized reagent in biology 
research, requires DMSO for in vitro applications. DMSO is known to have its own effects 
on cells and is also not suitable for in vivo applications. One of the strategies to overcome 
the challenge of delivering these hydrophobic agents is to utilize NPs. Many NPs, especially 
polymeric NPs, have hydrophobic cores and are well suited for the delivery of hydrophobic 
agents. The use of NP delivery vehicles not only overcomes the solubility of the active 
agent, but also protects the agent from the environment until the agent is released from NP. 
Our own group has demonstrated the proof-of-principle of this approach by developing a NP 
formulation of wortmannin.144 We demonstrated that NP wortmannin increased its 
solubility and improved its stability. We were also able to show that NP wortmannin has the 
same signaling effects on cells as wortmannin. Moreover, NP wortmannin functioned as an 
effective and potent therapeutic agent in vivo in a mouse model of cancer.
4.3.3 Delivering agents to subcellular organelles—One area of active investigation 
is delivering various agents to specific organelles. In particular, subcellular availability and 
accessibility of a target is important in effective delivery of therapeutic and imaging 
agents.145 Delivering agents to subcellular organelles can also potentially illuminate certain 
molecular processes that are still unknown in organelles.
The ability to easily modify and functionalize NPs has resulted in recent interest in using 
these vehicles to deliver agents to subcellular organelles. Targeted NPs can bind to targets 
localized on the cell surface and enter the cell through endocytosis. However, if the target is 
located intracellularly, NPs and their cargo may not be able to reach the target of interest due 
to intracellular sequestration of the NP or due to the lack of subcellular targeting 
capabilities. In particular, NPs carrying oligonucleotides need to escape the endosome and 
then be targeted to be effective. Tools for effective subcellular targeting are emerging for 
targeted delivery to the nucleus,146 cytosol,147 mitochondria,148 endosomes,149 and 
lysosomes.150 In general, two approaches are being investigated for the design of NPs for 
subcellular targeting: 1) Passive targeting of NPs to a particular organelle by varying NP 
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characteristics such as size, shape, and composition.151 2) Active targeting of NPs to the 
organelle of interest by functionalizing NP surfaces with targeting ligands directed towards 
the organelle. These approaches have been applied with varying levels of success.
Hurdles to successful sub-cellular targeting include biological barriers specific to the target 
organelle. For example, NPs targeted to the nucleus must enter the cell membrane, escape 
endosomal/lysosomal pathways, possess a way to interact with the nuclear pore complex, 
and be small enough to cross the nuclear membrane.146 Targeting ligands such as the 
nuclear localization signal (NLS) has been used to enhance nuclear delivery by active 
transport mechanism.152 In one study, the localization of NLS conjugated gold NPs at the 
nucleus of a cancer cell damaged the DNA.152 On the contrary, in another study, NLS 
conjugated gold NPs were not able to target the nucleus of cells from outside the plasma 
membrane because they were unable to enter the cells or were trapped in the endosomes. 
Instead, NPs conjugated with both NLS and receptor-mediated endocytosis (RME) peptides 
reached the nucleus.153
For NPs targeted to the mitochondria, biological barriers include intracellular transport to 
the mitochondria and outer and inner mitochondrial membranes and toxicity.154 Thus far, 
most studies have primarily developed metal oxide or liposomal NPs for delivery to the 
mitochondria. Delivery to the mitochondria has also been based on electrostatic interactions 
between the NP and the organelle. The mitochondria has a negative membrane potential 
compared to other cellular membranes, which can lead to the accumulation of liphophilic 
cations.155 This concept was utilized in the fabrication of stearyl triphenyl phosphonium 
(STPP) targeted liposomes with anti-cancer agents ceramide156 and scarleol157 to target the 
mitochondria. STPP was chosen since it exhibits both cationic and lipophilic properties. 
Another group used a polymeric NP system to deliver mitochondria-acting therapeutics to 
their destination.158 The NPs were synthesized with a lipophilic triphenylphosphonium 
(TPP) cation, which is known to cross into the mitochondrial matrix space. Through in vitro 
screening of a library of charge and size varied NPs, the group identified an optimized 
targeted NP that improved the efficacy and decreased the toxicity for cancer Alzheimer’s 
disease, and obesity compared with non-targeted NPs or the small molecule therapeutics.158
4.4 Effects of biology on NPs
Understanding NP interactions with biological systems is necessary in developing effective 
NPs as sensing, imaging and drug delivery agents. Thus, studies have increasingly focused 
on the biological effects of NP properties. Properties of NPs such as size, shape, functional 
groups, surface charge, and composition are all factors that have been shown to affect NP 
interactions with biological systems in vitro and in vivo.102 However, less work has been 
done to study the effects of biology on NPs. It is known that NPs are rapidly cleared by the 
cells of the reticuloendothelial system (RES)/mononuclear phagocyte system (MPS) in the 
body.103 To extend the circulation time of NPs in vivo, uncharged hydrophilic polymers 
such as PEG are often conjugated to the surface of particles for “stealthing”. Yet, antibodies 
against PEG can develop after the first administration of PEGylated particles. Understanding 
the biomolecular interactions of nanoparticles and the MPS is critical for the development of 
alternative methods for extending NP circulation times in vivo.
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Recently, it has been shown that the uptake of NPs by cells in vitro can be influenced by cell 
cycle phase.104 The study found that NPs internalized by cells are not exported from cells, 
but are split between daughter cells when the cell divides. The results may have implications 
on clearance or accumulation of NPs in vivo. Another recent study demonstrated that global 
immune status, such as the balance of Th1-Th2 cytokines and M1-M2 macrophages, can 
also affect the NP clearance process.105 The investigators showed that mouse strains that are 
prone to Th1 immune responses cleared NPs at a slower rate than Th2-prone mice. 
Macrophages isolated from the Th1 strains also took up fewer particles in vitro than 
macrophages from Th2 strains. Results were confirmed in human monocyte–derived 
macrophages, suggesting that global immune regulation may affect NP clearance in humans.
Due to their small sizes and the EPR effect, NPs are often passively or actively targeted to 
cancer tumors.106 Yet the clearance and distribution of NPs can also greatly depend on the 
tumor vasculature. Jain and colleagues have suggested that leaky and poorly organized 
blood vessels of cancerous tumors can result in an increase in the interstitial fluid pressure 
inside tumors, reducing blood supply to them and thus impairing delivery of agents to the 
tumors.107 They showed that repairing the abnormal vessels in mammary tumors, by 
blocking vascular endothelial growth factor receptor-2, improves the delivery of smaller 
NPs (12 nm), while hindering the delivery of larger (125 nm). The role of other proteins 
such as TGF-β in normalizing tumor vasculature for NP delivery in tumors has also been 
explored.108 TGF-β blockade was found to significantly decrease tumor growth and 
metastasis in mice. It also increased the recruitment and incorporation of perivascular cells 
into tumor blood vessels, increased the fraction of perfused vessels, and decreased the 
collagen I content of the tumor interstitial matrix. The investigators found that as a result of 
the vessel and interstitial matrix normalization, TGF-β blockade improved the intratumoral 
uptake of NP therapeutics, leading to better control of tumor growth.
4.5 Nanoparticles to study biological processes
The unique properties of NPs have enabled their use as promising tools to study biological 
processes. Many innovative techniques using NPs are being developed to activate cell 
signaling pathways, to induce protein production, and to improve upon current techniques 
used in molecular and cellular biology research. NPs such as QDs have been extensively 
studied for many biological applications that use fluorescence. Some of its uses include 
immunostaining of fixed cells and tissues, membrane proteins and cytoskeleton 
filaments.31, 159 Recently, QDs have also been used to visualize the molecular dynamics of 
individual molecules in live cells. One group visualized EGF-bound receptor movements by 
tagging a small fraction of individual EGFR molecules with a conjugate of one CdSe QD 
linked to one anti-EGFR antibody Fab fragment (antiEGFR–Fab).160 The individual 
antiEGFR–Fab-QD-bound EGFRs (EGFR–Fab-QD) were then visualized by total internal 
reflection fluorescence microscopy.
NP platforms can also enable the local perturbation of protein activities in cells at a 
subcellular scale. In particular, magnetic NPs can be coated with a biocompatible surface 
layer that can be functionalized with ligands that target specific cell-surface receptors, which 
then can be activated remotely by applied magnetic fields. In a recent study, investigators 
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used this approach to study how NP mediated activation of specific signaling pathways can 
lead to changes in cellular responses.161 The magnetic NPs are attached with active 
signaling proteins, and can be displaced by magnetic forces into different locations of the 
cell. Once these protein-conjugated NPs are inserted into the cells, they bind partner proteins 
to their surfaces and locally stimulate signal transduction pathways. This strategy was 
applied to members of the Rho-GTPases, a set of molecular switches known to regulate cell 
morphology. NP mediated Rac1 signal was found to induce actin polymerization in 
protrusive areas of cells while no NP induced actin polymerization was observed in the other 
areas of the cell, suggesting that Rac1 associates with another partner to polymerize actin in 
the regions of high membrane activity. The investigators demonstrated that the NP-mediated 
activation of signaling pathways could also lead to a local alteration of cellular morphology 
and remodeling of the actin cytoskeleton. Thus, the strategies used in this study could be 
used to enhance understanding of how other biomolecules are spatially modulated and 
integrated at the cellular level.
The use of magnetic NPs for controlling cell signaling pathways was demonstrated in 
another study by Cheon and colleagues.162 The group showed that functionalized magnetic 
NPs could turn on apoptosis cell signaling when a magnetic field is applied. The magnetic 
switch developed consisted of zinc-doped IONPs conjugated with a targeting antibody for 
death receptor 4 (DR4) of DLD-1 colon cancer cells. When a magnetic field is applied to 
aggregate DR4-conjugated IONPs bound to cell surface receptors, an apoptosis signaling 
pathway is promoted. This magnetic control of apoptosis was demonstrated in vivo using 
zebrafish as a model organism. IONPs can also be used to activate cells and remotely 
regulate protein production.163164 Stanley and colleagues used anti-His conjugated IONPs to 
bind to a modified epitope tagged TRPV1 channel. The temperature sensitive TRPV1 
channel is activated with local heating of bound anti-His IONPs, resulting in activation of a 
Ca2+-sensitive promoter that stimulates the synthesis and release of bioengineered insulin. 
This result along with lowered blood glucose was confirmed in vivo with mice expressing 
the bioengineered insulin gene. The investigators further showed that cells can be 
engineered to synthesize genetically encoded ferritin NPs and inducibly release insulin. The 
use of IONPs in noninvasive techniques for cell manipulation potentially provides a useful 
tool for basic biology research.
Other inorganic NP platforms have also shown potential as tools to regulate cellular 
activities with spatial and temporal control. Recently, infrared-absorbing gold NPs were 
used as optical switches of gene interference and were remotely controlled using light.165 
The technique involved functionalizing the NPs with double-stranded oligonucleotides and 
at specific times and intracellular locations, NIR illumination was used to photothermally 
heats the gold NPs, causing the double-stranded oligonucleotides to denature at their melting 
temperature and the antisense oligonucleotides to be released from the carriers.
On a macroscopic scale, the spatial organization of cells in cell culture can be important in 
basic biology research. Since cellular activities in conventional 2D cell culture differ from 
those found in vivo, many efforts have focused on developing 3D cell culture for a more 
physiologically relevant microenvironment. Recently, Pasqualini and colleagues reported an 
innovative approach to 3D tissue culture based on the magnetic levitation of cells with a 
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hydrogel consisting of gold NPs, IONPs, and M13-derived phage particles that display 
integrin-targeting ligands.163 By spatially controlling the magnetic field, the authors were 
able to control the geometry of the cell mass and produce concentrated clustering of 
different cell types in co-culture. They also found that magnetically levitated human 
glioblastoma cells showed similar protein expression profiles to those observed in human 
tumor xenografts. The results indicate that magnetic levitation of cells may be a useful 
method for recapitulating in vivo protein expression without the use of a specific medium, 
engineered scaffolds or matrices.
5. CONCLUSIONS AND FUTURE DIRECTIONS
Nanotechnology and NPs have a wide range of applications in biology. As mentioned above, 
nanotechnology enable the creation of devices on the same scale as individual cells and 
biomolecules, creating an unique approach to imaging, sensing, drug delivery and 
characterizing basic biological processes. Since the interest in biological application for NPs 
is very recent, there is reason for high optimism for more innovative and exciting 
applications of NPs in biology.
While a significant number of genes and proteins integral to biological processes have been 
identified, the manner in which many of these biological units and processes assemble and 
integrate still remains unknown. Biological studies that employ NP techniques can provide 
novel insights into cell functions and molecular processes involving complex signaling 
pathways. NPs can also be used to help understand how these processes can be 
constructively modified and how various components of a cell work together to accomplish 
a task. For instance, biological processes such as apoptosis, cell division, and stem cell fate 
are modulated by mechanical cues and changes in their physical environment. In 
understanding molecular mechanisms of mechanotransduction, NP analytical devices can be 
used to measure and manipulate interactions of biological molecules and cells to determine 
physical relationships between cellular components and understand how cells respond to 
mechanical forces and chemical cues.
NP monitoring and detection techniques can potentially aid in understanding the basis of 
biochemical pathways involved in disease and injury. NP sensors can enable the 
identification of biological molecules not addressable by current assays. Targeted NP 
systems can bind or react to the presence of these molecules with high affinity and 
selectivity, amplifying their signal for detection and molecular imaging. Furthermore, NPs 
can help overcome limitations associated with conventional delivery methods used in 
biological research such as insolubility and instability of hydrophobic compounds under 
aqueous conditions and nonspecific targeting. With significant progress in studying 
biological systems at the nanoscale and an integration of proteomics and genomics with 
nanotechnology, a deeper understanding of cell function and processes can be obtained that 
can in turn help in the design of novel nanoscale tools that may bring molecular systems 
back to normal operations after their function has been perturbed by disease. It is also 
important to note that as nanotechnology methods matures, there is less technical barrier for 
interested biologists to acquire NP techniques/platforms and adopt them into their own 
research. Currently, there are various commerical NPs available for use as contrast agents in 
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imaging modalities such fluorescence imaging and magnetic resonance imaging and for 
detection of low concentrations of analytes. However, as mentioned previously, NP 
properties such as size, shape, functional groups, surface charge, and composition are all 
factors that may affect NP interactions with biological systems in vitro and in vivo. Thus, 
careful evaluation of effects such as toxicity induced by different types of NP formulations 
in biological systems are important in employing NPs for biological applications. The full 
utilization of NP technology in biological research will require chemists and 
nanotechnologists to standardize and simplify NP fabrication techniques. It will also involve 
nanotechnology researchers actively engaging and collaborating with biologists to identify 
new areas of application and synergy.
ACKNOWLEDGEMENTS
This work is supported by grants from the University Cancer Research Fund from the University of North Carolina. 
Andrew Z. Wang is also supported by Career Development Award 5-K12-CA120780-01-05, National Institutes of 
Health Center for Nanotechnology Excellence Grant 1-U54-CA151652-01, and the National Academies Keck 
Futures Initiative Imaging Science Grant.
REFERENCES
1. Allhoff, F.; Lin, P.; Moore, D. What is nanotechnology and why does it matter? : from science to 
ethics. Chichester, UK ; Malden, MA: Wiley-Blackwell; 2010. p. xp. 293
2. Bangham AD. Liposomes: the Babraham connection. Chemistry and Physics of Lipids. 1993; 
64:275–285. DOI: http://dx.doi.org/10.1016/0009-3084(93)90071-A. [PubMed: 8242839] 
3. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 
2005; 4:145–160. [PubMed: 15688077] 
4. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature. 1989; 337:387–388. 
[PubMed: 2463491] 
5. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, 
Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. 
Proceedings of the National Academy of Sciences. 1987; 84:7413–7417.
6. Bangham AD. Liposomes-The Babraham Connection. Chem. Phys. Lipids. 1993; 64:275–285. 
[PubMed: 8242839] 
7. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. 
Advanced Drug Delivery Reviews. 2008; 60:876–885. DOI: http://dx.doi.org/10.1016/j.addr.
2007.08.044. [PubMed: 18423779] 
8. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. 
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor 
Oil–Based Paclitaxel in Women With Breast Cancer. J Clin Oncol. 2005; 23:7794–7803. [PubMed: 
16172456] 
9. Harries M, Ellis P, Harper P. Nanoparticle Albumin–Bound Paclitaxel for Metastatic Breast Cancer. 
Journal of Clinical Oncology. 2005; 23:7768–7771. [PubMed: 16204007] 
10. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opinion on 
Pharmacotherapy. 2006; 7:1041–1053. [PubMed: 16722814] 
11. Gref R, Minamitake Y, Peracchia M, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-
circulating polymeric nanospheres. Science. 1994; 263:1600–1603. [PubMed: 8128245] 
12. Chan, J.; Valencia, P.; Zhang, L.; Langer, R.; Farokhzad, O. Cancer Nanotechnology. Grobmyer, 
SR.; Moudgil, BM., editors. Vol. 624. Humana Press; 2010. p. 163-175.
13. Torchilin VP. Micellar Nanocarriers: Pharmaceutical Perspectives. Pharm Res. 2007; 24:1–16. 
[PubMed: 17109211] 
Wang and Wang Page 18






















14. Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR, Farokhzad OC. 
Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opinion on 
Biological Therapy. 2008; 8:1063–1070. [PubMed: 18613759] 
15. Medina SH, El-Sayed MEH. Dendrimers as Carriers for Delivery of Chemotherapeutic Agents. 
Chemical Reviews. 2009; 109:3141–3157. [PubMed: 19534493] 
16. Fréchet JMJ. Dendrimers and supramolecular chemistry. Proceedings of the National Academy of 
Sciences. 2002; 99:4782–4787.
17. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. 
Advanced Drug Delivery Reviews. 2005; 57:2106–2129. DOI: http://dx.doiorg/101016/
jaddr200509018. [PubMed: 16305813] 
18. Lee CC, MacKay JA, Frechet JMJ, Szoka FC. Designing dendrimers for biological applications. 
Nat Biotech. 2005; 23:1517–1526.
19. Mintzer MA, Grinstaff MW. Biomedical applications of dendrimers: a tutorial. Chemical Society 
Reviews. 2011; 40:173–190. [PubMed: 20877875] 
20. Weissleder R. Molecular Imaging in Cancer. Science. 2006; 312:1168–1171. [PubMed: 16728630] 
21. Daniel M-C, Astruc D. Gold Nanoparticles: Assembly, Supramolecular Chemistry, Quantum-Size-
Related Properties, and Applications toward Biology, Catalysis, and Nanotechnology. Chemical 
Reviews. 2003; 104:293–346. [PubMed: 14719978] 
22. Bulte JWM, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. 
NMR in Biomedicine. 2004; 17:484–499. [PubMed: 15526347] 
23. Wang Y-X, Hussain S, Krestin G. Superparamagnetic iron oxide contrast agents: physicochemical 
characteristics and applications in MR imaging. Eur Radiol. 2001; 11:2319–2331. [PubMed: 
11702180] 
24. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis 
using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001; 7:1241–1244. 
[PubMed: 11689890] 
25. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo 
magnetic resonance imaging of transgene expression. Nat Med. 2000; 6:351–354. [PubMed: 
10700241] 
26. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles 
(SPIONs): Development, surface modification and applications in chemotherapy. Advanced Drug 
Delivery Reviews. 2011; 63:24–46. DOI: http://dx.doi.org/10.1016/j.addr.2010.05.006. [PubMed: 
20685224] 
27. Collier CP, Vossmeyer T, Heath JR. NANOCRYSTAL SUPERLATTICES. Annual Review of 
Physical Chemistry. 1998; 49:371–404.
28. Jovin TM. Quantum dots finally come of age. Nat Biotech. 2003; 21:32–33.
29. Chang Y-P, Pinaud F, Antelman J, Weiss S. Tracking bio-molecules in live cells using quantum 
dots. Journal of Biophotonics. 2008; 1:287–298. [PubMed: 19343652] 
30. Chan WCW, Maxwell DJ, Gao XH, Bailey RE, Han MY, Nie SM. Luminescent quantum dots for 
multiplexed biological detection and imaging. Curr. Opin. Biotechnol. 2002; 13:40–46. [PubMed: 
11849956] 
31. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, Sundaresan G, Wu AM, Gambhir 
SS, Weiss S. Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics. Science. 2005; 
307:538–544. [PubMed: 15681376] 
32. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties 
and recent applications in cancer diagnostics and therapy. Nanomedicine. 2007; 2:681–693. 
[PubMed: 17976030] 
33. Nie S, Emory SR. Probing Single Molecules and Single Nanoparticles by Surface-Enhanced 
Raman Scattering. Science. 1997; 275:1102–1106. [PubMed: 9027306] 
34. Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten 
A, Haick H. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nano. 2009; 
4:669–673.
35. Liu X, Dai Q, Austin L, Coutts J, Knowles G, Zou J, Chen H, Huo Q. A One-Step Homogeneous 
Immunoassay for Cancer Biomarker Detection Using Gold Nanoparticle Probes Coupled with 
Wang and Wang Page 19






















Dynamic Light Scattering. Journal of the American Chemical Society. 2008; 130:2780–2782. 
[PubMed: 18257576] 
36. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer Cell Imaging and Photothermal Therapy in 
the Near-Infrared Region by Using Gold Nanorods. Journal of the American Chemical Society. 
2006; 128:2115–2120. [PubMed: 16464114] 
37. Marx V. Targeted proteomics. Nat Meth. 2013; 10:19–22.
38. Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the 
twenty-first century. Nat Rev Genet. 2005; 6:507–512. [PubMed: 15931173] 
39. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer 
T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, 
Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, 
Capdeville R, Druker BJ. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly 
Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine. 2003; 
348:994–1004. [PubMed: 12637609] 
40. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, 
Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher 
DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle 
JN, Wolmark N. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast 
Cancer. New England Journal of Medicine. 2005; 353:1673–1684. [PubMed: 16236738] 
41. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen 
HX, Rosenberg SA. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth 
Factor Antibody, for Metastatic Renal Cancer. New England Journal of Medicine. 2003; 349:427–
434. [PubMed: 12890841] 
42. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, 
Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP Chemotherapy plus Rituximab 
Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. New 
England Journal of Medicine. 2002; 346:235–242. [PubMed: 11807147] 
43. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 
7:653–664. [PubMed: 20838415] 
44. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect 
in macromolecular therapeutics: a review. J Control Release. 2000; 65:271–284. [PubMed: 
10699287] 
45. Verma A, Uzun O, Hu Y, Hu H-S, Han Y, Watson N, Chen S, Irvine DJ, Stellacci F. Surface-
structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater. 
2008; 7:588–595. [PubMed: 18500347] 
46. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. A Stepwise Huisgen Cycloaddition Process: 
Copper(I)-Catalyzed Regioselective“Ligation” of Azides and Terminal Alkynes. Angewandte 
Chemie International Edition. 2002; 41:2596–2599.
47. (a) Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. 
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the 
National Academy of Sciences. 2006; 103:6315–6320.(b) Werner ME, Copp JA, Karve S, 
Cummings ND, Sukumar R, Li C, Napier ME, Chen RC, Cox AD, Wang AZ. Folate-Targeted 
Polymeric Nanoparticle Formulation of Docetaxel Is an Effective Molecularly Targeted 
Radiosensitizer with Efficacy Dependent on the Timing of Radiotherapy. ACS Nano. 2011; 
5:8990–8998. [PubMed: 22011071] 
48. Saha K, Agasti SS, Kim C, Li X, Rotello VM. Gold Nanoparticles in Chemical and Biological 
Sensing. Chemical Reviews. 2012; 112:2739–2779. [PubMed: 22295941] 
49. Nam J-M, Thaxton CS, Mirkin CA. Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive 
Detection of Proteins. Science. 2003; 301:1884–1886. [PubMed: 14512622] 
50. Hill HD, Mirkin CA. The bio-barcode assay for the detection of protein and nucleic acid targets 
using DTT-induced ligand exchange. Nat. Protocols. 2006; 1:324–336.
51. Nam J-M, Wise AR, Groves JT. Colorimetric Bio-Barcode Amplification Assay for Cytokines. 
Analytical Chemistry. 2005; 77:6985–6988. [PubMed: 16255599] 
Wang and Wang Page 20






















52. Georganopoulou DG, Chang J-M, Nam L, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA. 
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for 
Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of 
America. 2005; 102:2273–2276. [PubMed: 15695586] 
53. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection 
and monitoring. Nat Rev Cancer. 2008; 8:268–278. [PubMed: 18337732] 
54. Thaxton CS, Elghanian R, Thomas AD, Stoeva SI, Lee J-S, Smith ND, Schaeffer AJ, Klocker H, 
Horninger W, Bartsch G, Mirkin CA. Nanoparticle-based bio-barcode assay redefines 
“undetectable” PSA and biochemical recurrence after radical prostatectomy. Proceedings of the 
National Academy of Sciences. 2009; 106:18437–18442.
55. Swierczewska M, Liu G, Lee S, Chen X. High-sensitivity nanosensors for biomarker detection. 
Chemical Society Reviews. 2012; 41:2641–2655. [PubMed: 22187721] 
56. You C-C, Miranda OR, Gider B, Ghosh I-B, Kim PS, Erdogan B, Krovi SA, Bunz UHF, Rotello 
VM. Detection and identification of proteins using nanoparticle-fluorescent polymer /`chemical 
nose/' sensors. Nat Nano. 2007; 2:318–323.
57. De M, Rana S, Akpinar H, Miranda OR, Arvizo RR, Bunz UHF, Rotello VM. Sensing of proteins 
in human serum using conjugates of nanoparticles and green fluorescent protein. Nat Chem. 2009; 
1:461–465. [PubMed: 20161380] 
58. Phillips RL, Miranda OR, You C-C, Rotello VM, Bunz UHF. Rapid and Efficient Identification of 
Bacteria Using Gold-Nanoparticle–Poly(para-phenyleneethynylene) Constructs. Angewandte 
Chemie International Edition. 2008; 47:2590–2594.
59. Bajaj A, Miranda OR, Kim I-B, Phillips RL, Jerry DJ, Bunz UHF, Rotello VM. Detection and 
differentiation of normal, cancerous, and metastatic cells using nanoparticle-polymer sensor 
arrays. Proceedings of the National Academy of Sciences. 2009; 106:10912–10916.
60. Bajaj A, Rana S, Miranda OR, Yawe JC, Jerry DJ, Bunz UHF, Rotello VM. Cell surface-based 
differentiation of cell types and cancer states using a gold nanoparticle-GFP based sensing array. 
Chemical Science. 2010; 1:134–138.
61. Shafer-Peltier KE, Haynes CL, Glucksberg MR, Van Duyne RP. Toward a Glucose Biosensor 
Based on Surface-Enhanced Raman Scattering. Journal of the American Chemical Society. 2002; 
125:588–593. [PubMed: 12517176] 
62. Xu H, Bjerneld EJ, Käll M, Börjesson L. Spectroscopy of Single Hemoglobin Molecules by 
Surface Enhanced Raman Scattering. Physical Review Letters. 1999; 83:4357–4360.
63. Yan B, Thubagere A, Premasiri WR, Ziegler LD, Dal Negro L, Reinhard BrM. Engineered SERS 
Substrates with Multiscale Signal Enhancement: Nanoparticle Cluster Arrays. ACS Nano. 2009; 
3:1190–1202. [PubMed: 19354266] 
64. Shanmukh S, Jones L, Driskell J, Zhao Y, Dluhy R, Tripp RA. Rapid and Sensitive Detection of 
Respiratory Virus Molecular Signatures Using a Silver Nanorod Array SERS Substrate. Nano 
Letters. 2006; 6:2630–2636. [PubMed: 17090104] 
65. Qian X, Peng X-H, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, Yang L, Young AN, Wang MD, 
Nie S. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman 
nanoparticle tags. Nat Biotech. 2008; 26:83–90.
66. Qian XM, Nie SM. Single-molecule and single-nanoparticle SERS: from fundamental mechanisms 
to biomedical applications. Chemical Society Reviews. 2008; 37:912–920. [PubMed: 18443676] 
67. Cecchini MP, Turek VA, Paget J, Kornyshev AA, Edel JB. Self-assembled nanoparticle arrays for 
multiphase trace analyte detection. Nat Mater. 2013; 12:165–171. [PubMed: 23160268] 
68. Haun JB, Yoon T-J, Lee H, Weissleder R. Magnetic nanoparticle biosensors. Wiley 
Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2010; 2:291–304. [PubMed: 
20336708] 
69. Wang SX, Li G. Advances in Giant Magnetoresistance Biosensors With Magnetic Nanoparticle 
Tags: Review and Outlook. Magnetics, IEEE Transactions on. 2008; 44:1687–1702.
70. Gaster RS, Hall DA, Nielsen CH, Osterfeld SJ, Yu H, Mach KE, Wilson RJ, Murmann B, Liao JC, 
Gambhir SS, Wang SX. Matrix-insensitive protein assays push the limits of biosensors in 
medicine. Nat Med. 2009; 15:1327–1332. [PubMed: 19820717] 
Wang and Wang Page 21






















71. Osterfeld SJ, Yu H, Gaster RS, Caramuta S, Xu S-J, Han L, Hall DA, Wilson RJ, Sun S, White 
RL, Davis RW, Pourmand N, Wang SX. Multiplex protein assays based on real-time magnetic 
nanotag sensing. Proceedings of the National Academy of Sciences. 2008; 105:20637–20640.
72. Fu A, Hu W, Xu L, Wilson RJ, Yu H, Osterfeld SJ, Gambhir SS, Wang SX. Protein-Functionalized 
Synthetic Antiferromagnetic Nanoparticles for Biomolecule Detection and Magnetic 
Manipulation. Angewandte Chemie International Edition. 2009; 48:1620–1624.
73. Shen T, Weissleder R, Papisov M, Bogdanov A, Brady TJ. Monocrystalline iron oxide 
nanocompounds (MION): Physicochemical properties. Magnetic Resonance in Medicine. 1993; 
29:599–604. [PubMed: 8505895] 
74. Josephson L, Tung C-H, Moore A, Weissleder R. High-Efficiency Intracellular Magnetic Labeling 
with Novel Superparamagnetic-Tat Peptide Conjugates. Bioconjugate Chemistry. 1999; 10:186–
191. [PubMed: 10077466] 
75. Perez JM, Josephson L, O'Loughlin T, Hogemann D, Weissleder R. Magnetic relaxation switches 
capable of sensing molecular interactions. Nat Biotech. 2002; 20:816–820.
76. Lee H, Sun E, Ham D, Weissleder R. Chip-NMR biosensor for detection and molecular analysis of 
cells. Nat Med. 2008; 14:869–874. [PubMed: 18607350] 
77. Connolly J, St Pierre TG. Proposed biosensors based on time-dependent properties of magnetic 
fluids. Journal of Magnetism and Magnetic Materials. 2001; 225:156–160. DOI: http://dx.doi.org/
10.1016/S0304-8853(00)01245-2. 
78. Fornara A, Johansson P, Petersson K, Gustafsson S, Qin J, Olsson E, Ilver D, Krozer A, 
Muhammed M, Johansson C. Tailored Magnetic Nanoparticles for Direct and Sensitive Detection 
of Biomolecules in Biological Samples. Nano Letters. 2008; 8:3423–3428. [PubMed: 18754596] 
79. Varshney M, Li Y. Interdigitated array microelectrode based impedance biosensor coupled with 
magnetic nanoparticle–antibody conjugates for detection of Escherichia coli O157:H7 in food 
samples. Biosensors and Bioelectronics. 2007; 22:2408–2414. DOI: http://dx.doi.org/10.1016/
j.bios.2006.08.030. [PubMed: 17045791] 
80. Xia N, Hunt T, Mayers B, Alsberg E, Whitesides G, Westervelt R, Ingber D. Combined 
microfluidic-micromagnetic separation of living cells in continuous flow. Biomed Microdevices. 
2006; 8:299–308. [PubMed: 17003962] 
81. Lee H, Yoon T-J, Weissleder R. Ultrasensitive Detection of Bacteria Using Core–Shell 
Nanoparticles and an NMR-Filter System. Angewandte Chemie International Edition. 2009; 
48:5657–5660.
82. Liong M, Hoang AN, Chung J, Gural N, Ford CB, Min C, Shah RR, Ahmad R, Fernandez-Suarez 
M, Fortune SM, Toner M, Lee H, Weissleder R. Magnetic barcode assay for genetic detection of 
pathogens. Nat Commun. 2013; 4:1752. [PubMed: 23612293] 
83. Chung HJ, Castro CM, Im H, Lee H, Weissleder R. A magneto-DNA nanoparticle system for rapid 
detection and phenotyping of bacteria. Nat Nano. 2013 advance online publication. 
84. El-Boubbou K, Gruden C, Huang X. Magnetic Glyco-nanoparticles: A Unique Tool for Rapid 
Pathogen Detection, Decontamination, and Strain Differentiation. Journal of the American 
Chemical Society. 2007; 129:13392–13393. [PubMed: 17929928] 
85. Pan Y, Du X, Zhao F, Xu B. Magnetic nanoparticles for the manipulation of proteins and cells. 
Chemical Society Reviews. 2012; 41:2912–2942. [PubMed: 22318454] 
86. Kell AJ, Stewart G, Ryan S, Peytavi R, Boissinot M, Huletsky A, Bergeron MG, Simard B. 
Vancomycin-Modified Nanoparticles for Efficient Targeting and Preconcentration of Gram-
Positive and Gram-Negative Bacteria. ACS Nano. 2008; 2:1777–1788. [PubMed: 19206416] 
87. Hill HD, Vega RA, Mirkin CA. Nonenzymatic Detection of Bacterial Genomic DNA Using the 
Bio Bar Code Assay. Analytical Chemistry. 2007; 79:9218–9223. [PubMed: 17927207] 
88. Zhang D, Carr DJ, Alocilja EC. Fluorescent bio-barcode DNA assay for the detection of 
Salmonella enterica serovar Enteritidis. Biosensors and Bioelectronics. 2009; 24:1377–1381. DOI: 
http://dx.doi.org/10.1016/j.bios.2008.07.081. [PubMed: 18835708] 
89. Edgar R, McKinstry M, Hwang J, Oppenheim AB, Fekete RA, Giulian G, Merril C, Nagashima K, 
Adhya S. High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot 
nanocomplexes. Proceedings of the National Academy of Sciences of the United States of 
America. 2006; 103:4841–4845. [PubMed: 16549760] 
Wang and Wang Page 22






















90. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, 
Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LWMM. Circulating Tumor 
Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer. Journal of 
Clinical Oncology. 2005; 23:1420–1430. [PubMed: 15735118] 
91. Miller MC, Doyle GV, Terstappen LWMM. Significance of Circulating Tumor Cells Detected by 
the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. Journal 
of Oncology. 2010; 2010
92. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, 
Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Meropol NJ. Relationship of 
Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in 
Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 2008; 26:3213–3221. 
[PubMed: 18591556] 
93. Xu H, Aguilar ZP, Yang L, Kuang M, Duan H, Xiong Y, Wei H, Wang A. Antibody conjugated 
magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials. 
2011; 32:9758–9765. DOI: http://dx.doi.org/10.1016/j.biomaterials.2011.08.076. [PubMed: 
21920599] 
94. Galanzha EI, Shashkov EV, Kelly J-W, Kim T, Yang L, Zharov VP. In vivo magnetic enrichment 
and multiplex photoacoustic detection of circulating tumour cells. Nat Nano. 2009; 4:855–860.
95. Myung JH, Gajjar KA, Han YE, Hong S. The role of polymers in detection and isolation of 
circulating tumor cells. Polymer Chemistry. 2012; 3:2336–2341.
96. Wang X, Qian X, Beitler JJ, Chen ZG, Khuri FR, Lewis MM, Shin HJC, Nie S, Shin DM. 
Detection of Circulating Tumor Cells in Human Peripheral Blood Using Surface-Enhanced Raman 
Scattering Nanoparticles. Cancer Research. 2011; 71:1526–1532. [PubMed: 21212408] 
97. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold 
nanoparticles for biomedicine. Chemical Society Reviews. 2012; 41:2740–2779. [PubMed: 
22109657] 
98. Karnik R, Hong S, Zhang H, Mei Y, Anderson DG, Karp JM, Langer R. Nanomechanical Control 
of Cell Rolling in Two Dimensions through Surface Patterning of Receptors. Nano Letters. 2008; 
8:1153–1158. [PubMed: 18321075] 
99. Choi S, Karp JM, Karnik R. Cell sorting by deterministic cell rolling. Lab on a Chip. 2012; 
12:1427–1430. [PubMed: 22327803] 
100. Myung JH, Gajjar KA, Saric J, Eddington DT, Hong S. Dendrimer-Mediated Multivalent Binding 
for the Enhanced Capture of Tumor Cells. Angewandte Chemie International Edition. 2011; 
50:11769–11772.
101. Lee J-H, Lee K, Moon SH, Lee Y, Park TG, Cheon J. All-in-One Target-Cell-Specific Magnetic 
Nanoparticles for Simultaneous Molecular Imaging and siRNA Delivery. Angewandte Chemie 
International Edition. 2009; 48:4174–4179.
102. Albanese A, Tang PS, Chan WC. The Effect of Nanoparticle Size, Shape, and Surface Chemistry 
on Biological Systems. Annual Review of Biomedical Engineering. 2012; 14:1–16.
103. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors Affecting the Clearance and 
Biodistribution of Polymeric Nanoparticles. Molecular Pharmaceutics. 2008; 5:505–515. 
[PubMed: 18672949] 
104. Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of 
nanoparticles in a cell population. Nat Nano. 2012; 7:62–68.
105. Jones SW, Roberts RA, Robbins GR, Perry JL, Kai MP, Chen K, Bo T, Napier ME, Ting JPY, 
DeSimone JM, Bear JE. Nanoparticle clearance is governed by Th1/Th2 immunity and strain 
background. The Journal of Clinical Investigation. 2013; 123:3061–3073. [PubMed: 23778144] 
106. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug 
delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev. 
2011; 63:136–151. DOI: http://dx.doi.org/10.1016/j.addr.2010.04.009. 
107. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, 
Fukumura D, Jain RK. Normalization of tumour blood vessels improves the delivery of 
nanomedicines in a size-dependent manner. Nat Nano. 2012; 7:383–388. DOI: http://
www.nature.com/nnano/journal/v7/n6/abs/nnano.2012.45.html#supplementary-information. 
Wang and Wang Page 23






















108. Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, Ancukiewicz M, Boucher Y, Jain 
RK, Xu L. TGF-β blockade improves the distribution and efficacy of therapeutics in breast 
carcinoma by normalizing the tumor stroma. Proceedings of the National Academy of Sciences. 
2012; 109:16618–16623.
109. Welch MJ, Hawker CJ, Wooley KL. The Advantages of Nanoparticles for PET. Journal of 
Nuclear Medicine. 2009; 50:1743–1746. [PubMed: 19837751] 
110. Cai W, Chen K, Li Z-B, Gambhir SS, Chen X. Dual-Function Probe for PET and Near-Infrared 
Fluorescence Imaging of Tumor Vasculature. Journal of Nuclear Medicine. 2007; 48:1862–1870. 
[PubMed: 17942800] 
111. Clarke S, Pinaud F, Beutel O, You C, Piehler J, Dahan M. Covalent Monofunctionalization of 
Peptide-Coated Quantum Dots for Single-Molecule Assays. Nano Letters. 2010; 10:2147–2154. 
[PubMed: 20433164] 
112. Howarth M, Liu W, Puthenveetil S, Zheng Y, Marshall LF, Schmidt MM, Wittrup KD, Bawendi 
MG, Ting AY. Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat 
Meth. 2008; 5:397–399.
113. Cai W, Shin D-W, Chen K, Gheysens O, Cao Q, Wang SX, Gambhir SS, Chen X. Peptide-
Labeled Near-Infrared Quantum Dots for Imaging Tumor Vasculature in Living Subjects. Nano 
Letters. 2006; 6:669–676. [PubMed: 16608262] 
114. Ballou B, Ernst LA, Andreko S, Harper T, Fitzpatrick JAJ, Waggoner AS, Bruchez MP. Sentinel 
Lymph Node Imaging Using Quantum Dots in Mouse Tumor Models. Bioconjugate Chemistry. 
2007; 18:389–396. [PubMed: 17263568] 
115. Lin S, Xie X, Patel Y-H, Yang M, Li Z, Cao F, Gheysens O, Zhang Y, Gambhir S, Rao J, Wu J. 
Quantum dot imaging for embryonic stem cells. BMC Biotechnology. 2007; 7:67. [PubMed: 
17925032] 
116. Kang WJ, Chae JR, Cho YL, Lee JD, Kim S. Multiplex Imaging of Single Tumor Cells Using 
Quantum-Dot-Conjugated Aptamers. Small. 2009; 5:2519–2522. [PubMed: 19714733] 
117. (a) Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and imaging with 
semiconductor quantum dots. Nat Biotech. 2004; 22:969–976.(b) Gao J, Chen K, Luong R, 
Bouley DM, Mao H, Qiao T, Gambhir SS, Cheng Z. A Novel Clinically Translatable Fluorescent 
Nanoparticle for Targeted Molecular Imaging of Tumors in Living Subjects. Nano Letters. 2011; 
12:281–286. [PubMed: 22172022] 
118. Samanta A, Maiti K-S, Soh KK, Liao X, Vendrell M, Dinish US, Yun S-W, Bhuvaneswari R, 
Kim H, Rautela S, Chung J, Olivo Y-T, Chang M. Ultrasensitive Near-Infrared Raman Reporters 
for SERS-Based In Vivo Cancer Detection. Angewandte Chemie International Edition. 2011; 
50:6089–6092.
119. Zavaleta CL, Smith BR, Walton I, Doering W, Davis G, Shojaei B, Natan MJ, Gambhir SS. 
Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using 
noninvasive Raman spectroscopy. Proceedings of the National Academy of Sciences. 2009; 
106:13511–13516.
120. Maiti KK, Dinish US, Samanta A, Vendrell M, Soh K-S, Park S-J, Olivo Y-T, Chang M. 
Multiplex targeted in vivo cancer detection using sensitive near-infrared SERS nanotags. Nano 
Today. 2012; 7:85–93. DOI: http://dx.doi.org/10.1016/j.nantod.2012.02.008. 
121. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Journeay WS, Subramani 
K, Laurent S. Magnetic Resonance Imaging Tracking of Stem Cells in Vivo Using Iron Oxide 
Nanoparticles as a Tool for the Advancement of Clinical Regenerative Medicine. Chemical 
Reviews. 2010; 111:253–280. [PubMed: 21077606] 
122. Chien L-Y, Hsiao J-K, Hsu S-C, Yao M, Lu C-W, Liu H-M, Chen Y-C, Yang C-S, Huang D-M. 
In vivo magnetic resonance imaging of cell tropsim, trafficking mechanism, and therapeutic 
impact of human mesenchymal stem cells in a murine glioma model. Biomaterials. 2011; 
32:3275–3284. DOI: http://dx.doi.org/10.1016/j.biomaterials.2011.01.042. [PubMed: 21295344] 
123. Bulte JWM, Douglas T, Witwer B, Zhang S-C, Strable E, Lewis BK, Zywicke H, Miller B, van 
Gelderen P, Moskowitz BM, Duncan ID, Frank JA. Magnetodendrimers allow endosomal 
magnetic labeling and in vivo tracking of stem cells. Nat Biotech. 2001; 19:1141–1147.
Wang and Wang Page 24






















124. Tung CH, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity 
using a novel molecular reporter. Cancer Research. 2000; 60:4953–4958. [PubMed: 10987312] 
125. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors 
on MR images using a long-circulating, superparamagnetic iron oxide agent. Journal of Magnetic 
Resonance Imaging. 1999; 9:228–232. [PubMed: 10077018] 
126. Leuschner C, Kumar C, Hansel W, Soboyejo W, Zhou J, Hormes J. LHRH-conjugated Magnetic 
Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases. Breast Cancer Research and 
Treatment. 2006; 99:163–176. [PubMed: 16752077] 
127. Lee J-H, Huh Y-M, Jun Y-w, Seo J-w, Jang J-t, Song H-T, Kim S, Cho E-J, Yoon H-G, Suh J-S, 
Cheon J. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. 
Nat Med. 2007; 13:95–99. [PubMed: 17187073] 
128. Park J-H, von Maltzahn G, Zhang L, Schwartz MP, Ruoslahti E, Bhatia SN, Sailor MJ. Magnetic 
Iron Oxide Nanoworms for Tumor Targeting and Imaging. Advanced Materials. 2008; 20:1630–
1635. [PubMed: 21687830] 
129. Ghosh D, Lee Y, Thomas S, Kohli AG, Yun DS, Belcher AM, Kelly KA. M13-templated 
magnetic nanoparticles for targeted in vivo imaging of prostate cancer. Nat Nano. 2012; 7:677–
682.
130. Fan K, Cao C, Pan Y, Lu D, Yang D, Feng J, Song L, Liang M, Yan X. Magnetoferritin 
nanoparticles for targeting and visualizing tumour tissues. Nat Nano. 2012; 7:459–464.
131. Soenen SJH, Hodenius M, De Cuyper M. Magnetoliposomes: versatile innovative nanocolloids 
for use in biotechnology and biomedicine. Nanomedicine. 2009; 4:177–191. [PubMed: 
19193184] 
132. Bulte JWM, de Cuyper M, Despres D, Frank JA. Short- vs. long-circulating magnetoliposomes as 
bone marrow-seeking MR contrast agents. Journal of Magnetic Resonance Imaging. 1999; 
9:329–335. [PubMed: 10077033] 
133. Khaled A, Guo S, Li F, Guo P. Controllable Self-Assembly of Nanoparticles for Specific 
Delivery of Multiple Therapeutic Molecules to Cancer Cells Using RNA Nanotechnology. Nano 
Letters. 2005; 5:1797–1808. [PubMed: 16159227] 
134. de Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J. Interfering with disease: a 
progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007; 6:443–453. [PubMed: 
17541417] 
135. Lebedeva I, Stein C. ANTISENSE OLIGONUCLEOTIDES: Promise and Reality. Annual 
Review of Pharmacology and Toxicology. 2001; 41:403–419.
136. Behlke MA. Progress towards in Vivo Use of siRNAs. Mol Ther. 2006; 13:644–670. [PubMed: 
16481219] 
137. Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, Karagiannis E, Love K, Chen 
D, Zoncu R, Buganim Y, Schroeder A, Langer R, Anderson DG. Efficiency of siRNA delivery 
by lipid nanoparticles is limited by endocytic recycling. Nat Biotech. 2013; 31:653–658.
138. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular 
delivery of therapeutics. CMLS, Cell. Mol. Life Sci. 2005; 62:1839–1849.
139. Alabi CA, Sahay G, Langer R, Anderson DG. Development of siRNA-probes for studying 
intracellular trafficking of siRNA nanoparticles. Integrative Biology. 2013; 5:224–230. [PubMed: 
23014672] 
140. Alabi CA, Love KT, Sahay G, Stutzman T, Young WT, Langer R, Anderson DG. FRET-Labeled 
siRNA Probes for Tracking Assembly and Disassembly of siRNA Nanocomplexes. ACS Nano. 
2012; 6:6133–6141. [PubMed: 22693946] 
141. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic Leukocyte-Directed siRNA 
Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target. Science. 2008; 319:627–630. 
[PubMed: 18239128] 
142. Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, Querbes W, Ge P, 
Ruda VM, Milstein S, Speciner L, Duncan R, Barros S, Basha G, Cullis P, Akinc A, Donahoe JS, 
Narayanannair Jayaprakash K, Jayaraman M, Bogorad RL, Love K, Whitehead K, Levins C, 
Manoharan M, Swirski FK, Weissleder R, Langer R, Anderson DG, de Fougerolles A, 
Wang and Wang Page 25






















Nahrendorf M, Koteliansky V. Systemic RNAi-mediated Gene Silencing in Nonhuman Primate 
and Rodent Myeloid Cells. Mol Ther Nucleic Acids. 2012; 1:e4. [PubMed: 23344621] 
143. Silva A, Nguyen A, Ye C, Verchot J, Moon J. Conjugated polymer nanoparticles for effective 
siRNA delivery to tobacco BY-2 protoplasts. BMC Plant Biology. 2010; 10:291. [PubMed: 
21192827] 
144. Karve S, Werner ME, Sukumar R, Cummings ND, Copp JA, Wang EC, Li C, Sethi M, Chen RC, 
Pacold ME, Wang AZ. Revival of the abandoned therapeutic wortmannin by nanoparticle drug 
delivery. Proceedings of the National Academy of Sciences of the United States of America. 
2012; 109:8230–8235. [PubMed: 22547809] 
145. Rajendran L, Knolker H-J, Simons K. Subcellular targeting strategies for drug design and 
delivery. Nat Rev Drug Discov. 2010; 9:29–42. [PubMed: 20043027] 
146. Pouton CW, Wagstaff KM, Roth DM, Moseley GW, Jans DA. Targeted delivery to the nucleus. 
Advanced Drug Delivery Reviews. 2007; 59:698–717. DOI: http://dx.doi.org/10.1016/j.addr.
2007.06.010. [PubMed: 17681634] 
147. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. 
Advanced Drug Delivery Reviews. 2007; 59:718–728. DOI: http://dx.doi.org/10.1016/j.addr.
2007.06.003. [PubMed: 17683826] 
148. Yamada Y, Harashima H. Mitochondrial drug delivery systems for macromolecule and their 
therapeutic application to mitochondrial diseases. Advanced Drug Delivery Reviews. 2008; 
60:1439–1462. DOI: http://dx.doi.org/10.1016/j.addr.2008.04.016. [PubMed: 18655816] 
149. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Advanced Drug 
Delivery Reviews. 2007; 59:748–758. DOI: http://dx.doi.org/10.1016/j.addr.2007.06.008. 
[PubMed: 17659804] 
150. Lloyd JB. Lysosome membrane permeability: implications for drug delivery. Advanced Drug 
Delivery Reviews. 2000; 41:189–200. DOI: http://dx.doi.org/10.1016/S0169-409X(99)00065-4. 
[PubMed: 10699314] 
151. Xu ZP, Niebert M, Porazik K, Walker TL, Cooper HM, Middelberg APJ, Gray PP, Bartlett PF, 
Lu GQ. Subcellular compartment targeting of layered double hydroxide nanoparticles. Journal of 
Controlled Release. 2008; 130:86–94. DOI: http://dx.doi.org/10.1016/j.jconrel.2008.05.021. 
[PubMed: 18614254] 
152. Kang B, Mackey MA, El-Sayed MA. Nuclear Targeting of Gold Nanoparticles in Cancer Cells 
Induces DNA Damage, Causing Cytokinesis Arrest and Apoptosis. Journal of the American 
Chemical Society. 2010; 132:1517–1519. [PubMed: 20085324] 
153. Tkachenko AG, Xie H, Coleman D, Glomm W, Ryan J, Anderson MF, Franzen S, Feldheim DL. 
Multifunctional Gold Nanoparticle–Peptide Complexes for Nuclear Targeting. Journal of the 
American Chemical Society. 2003; 125:4700–4701. [PubMed: 12696875] 
154. Durazo SA, Kompella UB. Functionalized nanosystems for targeted mitochondrial delivery. 
Mitochondrion. 2012; 12:190–201. DOI: http://dx.doi.org/10.1016/j.mito.2011.11.001. [PubMed: 
22138492] 
155. Breunig M, Bauer S, Goepferich A. Polymers and nanoparticles: Intelligent tools for intracellular 
targeting? European Journal of Pharmaceutics and Biopharmaceutics. 2008; 68:112–128. DOI: 
http://dx.doi.org/10.1016/j.ejpb.2007.06.010. [PubMed: 17804211] 
156. Boddapati SV, D’Souza GGM, Erdogan S, Torchilin VP, Weissig V. Organelle-Targeted 
Nanocarriers: Specific Delivery of Liposomal Ceramide to Mitochondria Enhances Its 
Cytotoxicity in Vitro and in Vivo. Nano Letters. 2008; 8:2559–2563. [PubMed: 18611058] 
157. Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, D’Souza 
GG. Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. 
Journal of Liposome Research. 2010; 20:244–249. [PubMed: 19883213] 
158. Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-
acting therapeutics. Proceedings of the National Academy of Sciences. 2012; 109:16288–16293.
159. Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, Chung LW, Petros JA, O'Regan RM, 
Yezhelyev MV, Simons JW, Wang MD, Nie S. Bioconjugated quantum dots for multiplexed and 
quantitative immunohistochemistry. Nat. Protocols. 2007; 2:1152–1165.
Wang and Wang Page 26






















160. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. Spatial control of EGF 
receptor activation by reversible dimerization on living cells. Nature. 2010; 464:783–787. 
[PubMed: 20208517] 
161. Etoc F, Lisse D, Bellaiche Y, Piehler J, Coppey M, Dahan M. Subcellular control of Rac-GTPase 
signalling by magnetogenetic manipulation inside living cells. Nat Nano. 2013; 8:193–198.
162. Cho MH, Lee EJ, Son M, Lee J-H, Yoo D, Kim J-w, Park SW, Shin J-S, Cheon J. A magnetic 
switch for the control of cell death signalling in in vitro and in vivo systems. Nat Mater. 2012; 
11:1038–1043. [PubMed: 23042417] 
163. Souza GR, Molina JR, Raphael RM, Ozawa MG, Stark DJ, Levin CS, Bronk LF, Ananta JS, 
Mandelin J, Georgescu M-M, Bankson JA, Gelovani JG, Killian TC, Arap W, Pasqualini R. 
Three-dimensional tissue culture based on magnetic cell levitation. Nat Nano. 2010; 5:291–296.
164. Stanley SA, Gagner JE, Damanpour S, Yoshida M, Dordick JS, Friedman JM. Radio-Wave 
Heating of Iron Oxide Nanoparticles Can Regulate Plasma Glucose in Mice. Science. 2012; 
336:604–608. [PubMed: 22556257] 
165. Lee SE, Liu GL, Kim F, Lee LP. Remote Optical Switch for Localized and Selective Control of 
Gene Interference. Nano Letters. 2009; 9:562–570. [PubMed: 19128006] 
Wang and Wang Page 27























Schematic representation of different types of nanoparticles.
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The bio-barcode method. A. Development of the NP probe. B. Method of detection using 
prostate specific antigen-conjugated gold NP probes. Reproduced from Ref. 55.
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Interactions between NP-GFP complexes and cell surfaces generates different fluorescence 
patterns. Reproduced from Ref. 60.
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Surface-enhanced Raman scattering (SERS) spectra and the correlated surface plasmon 
imaging of single cancer cells tagged with ScFv-conjugated gold NPs. Reproduced from 
Ref. 66.
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Depiction of bacteria detection by magnetic glyco-NPs (MGNPs). Reproduced from Ref. 85.
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Enhance surface-enhanced Raman scattering (SERS) detection of circulating tumor cells. A) 
Schematic of EGF peptide-conjugated NPs. B) SERS spectra of different numbers of cancer 
cells spiked into white blood cell sample. C) SERS spectra of a blood sample incubated with 
targeted and non-targeted NPs. Reproduced from Ref. 97.
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